Some Posts from yesterday.......
Posted by: Craig 305
Re: RisingMT Post# 19563
PSN posted a share structure update yesterday. He contacts the TA directly.
Float was 140.5 million.
Increased 1.5 million over the previous week.
Posted by: Itsthebox1:
Re: Craig305 Post# 19528
Max $10k per day, that is 150,000 shares, not a problem
Replies:
In that case, the Eagle loan is adding
Craig305 on 10/3/2017 7:01:12 PM
Posted by: retired early
Re: PyschoNoobStock Post# 19549
TKS. “We are very excited about these interim results,” stated Endonovo CEO,
BUYOUT CANDIDATE ALERT
Replies:
This heading way up. .136 was last run
Pennystock9449 on 10/3/2017 6:58:38 PM
Posted by: PyschoNoobStock
Endonovo Therapeutics Inc (OTCMKTS:ENDV) Squeezes Higher on Recent Update
Jermaine Farmer - October 3, 2017
Endonovo Therapeutics Inc (OTCMKTS:ENDV) is a penny stock that’s clearly begun to spur some interest among players in the marketplace as shares bounce up off recent lows. The action in this stock has been red-hot over the past two weeks, helped along by the company’s recent announcement of an update on its pre-clinical studies and interim results from its pre-clinical study to assess the effectiveness of its Immunotronics platform in the treatment and prevention of heart failure following myocardial infarction.
According to the release, “Interim results from the Company’s ongoing pre-clinical study to assess the effectiveness of its Immunotronics platform in the treatment and prevention of heart failure following myocardial infarction have demonstrated improved cardiac function and less ventricular remodeling, as evaluated using echocardiography in infarcted animals treated with the Company’s non-invasive electroceutical two or three times per day for four weeks when compared to the control group. The Company expects to provide final results including histology and cytokine data in the next few weeks.”
Endonovo Therapeutics Inc (OTCMKTS:ENDV) bills itself as an innovative biotechnology company developing a bioelectronic approach to regenerative medicine.
Endonovo’s Immunotronics platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation and necrosis, and the promotion of regeneration. Endonovo’s Cytotronics platform provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields (TVEMF) for tissue engineering and cell therapies.
According to company materials, “Endonovo Therapeutics, Inc. is a leading developer of bioelectronic-enhanced cell therapies and non-invasive electroceuticals. Endonovo’s Immunotronics platform is dedicated to treating patients with vascular diseases and life-threatening inflammatory conditions in vital organs using proprietary non-invasive electroceutical devices. The Company’s non-invasive platform is based on magnetically-induced electrical field pathways that target the disruption of inflammation and cell death. The Company’s Cytotronics platform harnesses the bulk electrical properties of cells and tissues, namely magnetically-induced electrical field pathways to expand and enhance the therapeutic potential of cell therapies and produce next-generation biologics.”
As noted above, the stock has been popping of late, fueled by the company’s recent update showing improved cardiac function and less ventricular remodeling with the involvement of its Immunotronics pipeline asset. One must also remember that this stock is trading on a float that, according to OTCmarkets.com, is well under 1M shares, making it one of the lightest floats we have ever covered.
The combination of strong data and that type of float can have only one outcome: a recent explosive move to the upside.
“We are very excited about these interim results,” stated Endonovo CEO, Alan Collier. “We not only want to demonstrate the effectiveness of our non-invasive electroceutical, but we also want to create an easy-to-use device that can reduce the treatment time required to produce a meaningful effect. Our belief is that the future of medicine is electric and that our non-implantable and non-invasive electroceutical platform will be at the forefront of bioelectronic medicine,” said Mr. Collier.
Overall, we’ve witnessed a bit more than 140% tacked on to share pricing for the company in the past month, a bounce that has taken root amid largely bearish action over the larger time frame. However, ENDV has a history of dramatic rallies. What’s more, the name has benefitted from a jump in recent trading volume to the tune of 92% over what the stock has registered over the longer term.
Traders should note this as important given the stock’s tiny trading float of roughly 620K shares, as discussed above. As savvy traders are well aware, ramping trading activity can overwhelm available supply in a stock with this type of small float, leading to an upward burst in prices.
Now commanding a market cap of $16.56M, ENDV has virtually no cash on the books, which compares with about $2.4M in total current liabilities. One should also note that debt has been growing over recent quarters. The company is pre-revenue at this point. This may be a very interesting story and we will look forward to updating it again soon. Sign-up for continuing coverage on shares of $ENDV stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $ENDV, either long or short, and we have not been compensated for this article.
http://oracledispatch.com/2017/10/03/endonovo...nt-update/
Replies:
Nice! The word is getting out on
CommonCents3 on 10/3/2017 5:21:04 PM
Great read, should be posted on the pin
Bigtoker on 10/3/2017 5:45:11 PM
Very nice article....
fly_fisherman on 10/3/2017 6:01:03 PM
TKS. “We are very excited about these interim
retired early on 10/3/2017 6:25:36 PM
Is the info in the article accurate? There's
RisingMT on 10/3/2017 9:00:25 PM
Posted by: Craig 305
Re: RisingMT Post# 19563
PSN posted a share structure update yesterday. He contacts the TA directly.
Float was 140.5 million.
Increased 1.5 million over the previous week.
Posted by: Itsthebox1:
Re: Craig305 Post# 19528
Max $10k per day, that is 150,000 shares, not a problem
Replies:
In that case, the Eagle loan is adding
Craig305 on 10/3/2017 7:01:12 PM
Posted by: retired early
Re: PyschoNoobStock Post# 19549
TKS. “We are very excited about these interim results,” stated Endonovo CEO,
BUYOUT CANDIDATE ALERT
Replies:
This heading way up. .136 was last run
Pennystock9449 on 10/3/2017 6:58:38 PM
Posted by: PyschoNoobStock
Endonovo Therapeutics Inc (OTCMKTS:ENDV) Squeezes Higher on Recent Update
Jermaine Farmer - October 3, 2017
Endonovo Therapeutics Inc (OTCMKTS:ENDV) is a penny stock that’s clearly begun to spur some interest among players in the marketplace as shares bounce up off recent lows. The action in this stock has been red-hot over the past two weeks, helped along by the company’s recent announcement of an update on its pre-clinical studies and interim results from its pre-clinical study to assess the effectiveness of its Immunotronics platform in the treatment and prevention of heart failure following myocardial infarction.
According to the release, “Interim results from the Company’s ongoing pre-clinical study to assess the effectiveness of its Immunotronics platform in the treatment and prevention of heart failure following myocardial infarction have demonstrated improved cardiac function and less ventricular remodeling, as evaluated using echocardiography in infarcted animals treated with the Company’s non-invasive electroceutical two or three times per day for four weeks when compared to the control group. The Company expects to provide final results including histology and cytokine data in the next few weeks.”
Endonovo Therapeutics Inc (OTCMKTS:ENDV) bills itself as an innovative biotechnology company developing a bioelectronic approach to regenerative medicine.
Endonovo’s Immunotronics platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation and necrosis, and the promotion of regeneration. Endonovo’s Cytotronics platform provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields (TVEMF) for tissue engineering and cell therapies.
According to company materials, “Endonovo Therapeutics, Inc. is a leading developer of bioelectronic-enhanced cell therapies and non-invasive electroceuticals. Endonovo’s Immunotronics platform is dedicated to treating patients with vascular diseases and life-threatening inflammatory conditions in vital organs using proprietary non-invasive electroceutical devices. The Company’s non-invasive platform is based on magnetically-induced electrical field pathways that target the disruption of inflammation and cell death. The Company’s Cytotronics platform harnesses the bulk electrical properties of cells and tissues, namely magnetically-induced electrical field pathways to expand and enhance the therapeutic potential of cell therapies and produce next-generation biologics.”
As noted above, the stock has been popping of late, fueled by the company’s recent update showing improved cardiac function and less ventricular remodeling with the involvement of its Immunotronics pipeline asset. One must also remember that this stock is trading on a float that, according to OTCmarkets.com, is well under 1M shares, making it one of the lightest floats we have ever covered.
The combination of strong data and that type of float can have only one outcome: a recent explosive move to the upside.
“We are very excited about these interim results,” stated Endonovo CEO, Alan Collier. “We not only want to demonstrate the effectiveness of our non-invasive electroceutical, but we also want to create an easy-to-use device that can reduce the treatment time required to produce a meaningful effect. Our belief is that the future of medicine is electric and that our non-implantable and non-invasive electroceutical platform will be at the forefront of bioelectronic medicine,” said Mr. Collier.
Overall, we’ve witnessed a bit more than 140% tacked on to share pricing for the company in the past month, a bounce that has taken root amid largely bearish action over the larger time frame. However, ENDV has a history of dramatic rallies. What’s more, the name has benefitted from a jump in recent trading volume to the tune of 92% over what the stock has registered over the longer term.
Traders should note this as important given the stock’s tiny trading float of roughly 620K shares, as discussed above. As savvy traders are well aware, ramping trading activity can overwhelm available supply in a stock with this type of small float, leading to an upward burst in prices.
Now commanding a market cap of $16.56M, ENDV has virtually no cash on the books, which compares with about $2.4M in total current liabilities. One should also note that debt has been growing over recent quarters. The company is pre-revenue at this point. This may be a very interesting story and we will look forward to updating it again soon. Sign-up for continuing coverage on shares of $ENDV stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $ENDV, either long or short, and we have not been compensated for this article.
http://oracledispatch.com/2017/10/03/endonovo...nt-update/
Replies:
Nice! The word is getting out on
CommonCents3 on 10/3/2017 5:21:04 PM
Great read, should be posted on the pin
Bigtoker on 10/3/2017 5:45:11 PM
Very nice article....
fly_fisherman on 10/3/2017 6:01:03 PM
TKS. “We are very excited about these interim
retired early on 10/3/2017 6:25:36 PM
Is the info in the article accurate? There's
RisingMT on 10/3/2017 9:00:25 PM
